Evidence map›Paper›PMID 30166856›Full record

ReviewWorld journal of gastroenterology2018

Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer.

Daniela Cornelia Lazăr, Mihaela Flavia Avram, Ioan Romoșan, Mărioara Cornianu, Sorina Tăban, Adrian Goldiș

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers.

0numbers the graph read from it
0cells of the map it votes in
98citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

98 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Thoracic Radiation on Survival in Patients with Advanced Small Cell Lung Cancer Treated with Chemoimmunotherapy.Medical science monitor : international medical journal of experimental and clinical research · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

38 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Daniela Cornelia LazărDepartment of Internal Medicine I, University Medical Clinic, University of Medicine and Pharmacy "Victor Babeş", Timişoara 300041, Timiş County, Romania. lazar.daniela@umft.ro.
Mihaela Flavia AvramDepartment of Surgery X, 1 Surgery Clinic, University of Medicine and Pharmacy "Victor Babeş", Timişoara 300041, Timiş County, Romania.
Ioan RomoșanDepartment of Internal Medicine I, University Medical Clinic, University of Medicine and Pharmacy "Victor Babeş", Timişoara 300041, Timiş County, Romania.
Mărioara CornianuDepartment of Pathology, University of Medicine and Pharmacy "Victor Babeş", Timişoara 300041, Timiş County, Romania.
Sorina TăbanDepartment of Pathology, University of Medicine and Pharmacy "Victor Babeş", Timişoara 300041, Timiş County, Romania.
Adrian GoldișDepartment of Gastroenterology and Hepatology, University of Medicine and Pharmacy "Victor Babeş", Timişoara 300041, Timiş County, Romania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite a decrease in gastric cancer incidence, the development of novel biologic agents and combined therapeutic strategies, the prognosis of gastric cancer remains poor. Recently, the introduction of modern immunotherapy, especially using immune checkpoint inhibitors, led to an improved prognosis in many cancers. The use of immunotherapy was also associated with manageable adverse event profiles and promising results in the treatment of patients with gastric cancer, especially in heavily pretreated patients. These data have led to an accelerated approval of some checkpoint inhibitors in this setting. Understanding the complex relationship between the host immune microenvironment and tumor and the immune escape phenomenon leading to cancer occurrence and progression will subsequently lead to the identification of prognostic immune markers. Furthermore, this understanding will result in the discovery of both new mechanisms for blocking tumor immunosuppressive signals and pathways to stimulate the local immune response by targeting and modulating different subsets of immune cells. Due to the molecular heterogeneity of gastric cancers associated with different clinico-biologic parameters, immune markers expression and prognosis, novel immunotherapy algorithms should be personalized and addressed to selected subsets of gastric tumors, which have been proven to elicit the best clinical responses. Future perspectives in the treatment of gastric cancer include tailored dual immunotherapies or a combination of immunotherapy with other targeted agents with synergistic antitumor effects.

Indexed as

Antineoplastic Agents, ImmunologicalBiological ProductsBiomarkers, TumorCostimulatory and Inhibitory T-Cell ReceptorsHumansImmunotherapyMolecular Targeted TherapyPrognosisSignal TransductionStomach NeoplasmsTreatment OutcomeTumor MicroenvironmentAntineoplastic Agents, ImmunologicalBiological ProductsBiomarkers, TumorCostimulatory and Inhibitory T-Cell ReceptorsGastric cancerImmune checkpoint inhibitorsImmunotherapyPrognostic significanceTumor immune microenvironment

Identifiers

PMID30166856
PMCPMC6113718

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.